We focus on metabolic, inflammatory, and renal diseases with high unmet need
Learn about our clinical-stage candidates
INNOVATION IN METABOLIC SCIENCE
Transforming Treatment for Metabolic, Inflammatory, and Renal Diseases
We focus on metabolic, inflammatory, and renal diseases with high unmet need
We are a research-driven biopharmaceutical company developing innovative oral small-molecule therapies for obesity, chronic kidney disease (CKD), and inflammation-driven disorders. By uniting AI/ML discovery, medicinal chemistry, and translational biology, we design differentiated medicines and progress them efficiently through preclinical development toward first-in-human studies.
Our integrated AI/ML R&D platform accelerates target selection, molecule design, and de-risking, while our Biological Research Platform provides human-relevant in vitro/ex vivo systems and in vivo disease models to generate robust, decision-ready data. This end-to-end approach shortens the path from insight to candidate and keeps patient needs at the center of our work.
Backed by a collaborative network of partners and advisors, we are advancing a next wave of oral therapies aimed at reducing inflammation, restoring metabolic balance, and improving kidney health—to deliver meaningful outcomes for patients worldwide.
ADVANCING HUMAN HEALTH
Our Focus Areas
We target chronic inflammatory processes that cause major health complications. Our programs span multiple pathways—including NLRP3, GPR75, and related nodes—and are built as brain-permeable or systemic candidates to match the biology.
Kidney Disease
Sterile Inflammation
Neuroinflammation
Cardiovascular
OUR TEAM
The People Behind Mwyngil
Our team unites leaders in biotechnology, medicine, and data science with a shared mission to translate groundbreaking biology into new therapies.
Nikolay Savchuk
PhD,
CEO
Vasily Kazey
PhD,
Head Pharmacology
Alexander Khvat
PhD,
Head MedChem
Claudia Filozof
MD PhD,
Head Clinical Development interim,
Endocrinology
Boris Rogovoy
PhD,
Head of Chemistry
Steph Mowery
PhD,
Head Biology
Srini Natala
PhD,
Lead MedChem
Ruben Karapetyan
PhD,
Head Development
Iain Dukes
Venture Partner
OrbiMed, CEO
Nikolay Savchuk
Managing Partner
Torrey Pines Investment
Eddie Wang Rodriguez
General Partner
Teal Ventures
Carl Gordon Chairman
General Partner
OrbiMed
Plamen Penev
MD PhD
Medical Affairs, Diabetes
Slava Gedulin
MD PhD
Louis Philipson
MD, PhD,
James C. Tyree
Professor of Diabetes,
UChicago
Prof Pierluigi Nicotera
MD, PhD
Scientific Director and Chairman of the Executive Board of DZNE, Advisor
Raghu Mirmira
MD, PhD,
Director of the Department of Med Translational Research Center
UChicago
Investors
Empowered by our world-class investors, we advance the discovery and development of next-generation therapies for obesity, chronic kidney disease, and inflammatory disorders — united by a shared mission to improve patient lives globally.
CONTACT US
Contact with Mwyngil
Whether you’re exploring partnership opportunities or seeking information about our research, we’d be glad to hear from you.
